Tempest Therapeutics
TPST
17 hedge funds and large institutions have $12.4M invested in Tempest Therapeutics in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
14% more capital inflows, than outflows
Capital inflows: $5.76M | Capital outflows: $5.05M
1.31% more ownership
Funds ownership: 32.69% → 34.01% (+1.3%)
15% less funds holding
Funds holding: 20 → 17 (-3)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $17K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rock Springs Capital Management
Baltimore,
Maryland
|
+$5.44M |
| 2 |
Renaissance Technologies
New York
|
+$173K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$117K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$29.1K |
| 5 |
BlackRock
New York
|
+$3.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Foresite Capital Management IV
Larkspur,
California
|
-$2.75M |
| 2 |
Monashee Investment Management
Boston,
Massachusetts
|
-$868K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$719K |
| 4 |
Maven Securities
St Helier,
Jersey
|
-$525K |
| 5 |
Millennium Management
New York
|
-$153K |
TPST Hedge Fund Activity: Q4 2021 in Review
17 of the 6,521 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2021, worth a combined $12.4M — down 61% from $31.7M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TPST and 1 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Rock Springs Capital Management, adding an estimated $5.44M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $2.75M sold.
- 17 institutional investors held Tempest Therapeutics (TPST) as of Q4 2021, down from 20 in Q3 2021.
- Funds reported $12.4M of Tempest Therapeutics stock for Q4 2021, down 61% quarter-over-quarter.
- 1 fund opened new Tempest Therapeutics positions in Q4 2021 and 4 closed out, a net change of -3 holders.
- The largest Tempest Therapeutics buyer in Q4 2021 was Rock Springs Capital Management, an estimated $5.44M added.
- The largest Tempest Therapeutics seller in Q4 2021 was Foresite Capital Management IV, an estimated $2.75M sold.
Based on aggregated 13F filings for Q4 2021.